LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells

Cancer Invest. 2011 Feb;29(2):153-61. doi: 10.3109/07357907.2010.543217.

Abstract

Low-molecular-weight heparins (LMWH) are anticoagulant drugs that also possess antitumor properties. We evaluated whether "second generation" LMWH bemiparin and the Ultra-Low-MWH (ULMWH) RO-14 are able to inhibit in vitro the angiogenic response of microvascular endothelium stimulated by tumor-cell-conditioned media (TCM) from human leukemia, lung cancer, and breast cancer cells. Bemiparin and RO-14 dose dependently inhibited the increase of capillary-like tube formation (Matrigel-based assay) and endothelial migration (wound-healing assay) induced by TCM. Both drugs also inhibited angiogenic response elicited by purified VEGF and FGF-2. These findings support a possible role of these molecules as adjuvant drugs in cancer treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Breast Neoplasms / blood supply*
  • Breast Neoplasms / drug therapy
  • Cell Line, Tumor
  • Endothelial Cells / drug effects*
  • Female
  • Fibroblast Growth Factor 2 / physiology
  • Heparin, Low-Molecular-Weight / pharmacology*
  • Humans
  • Leukemia / drug therapy
  • Leukemia / physiopathology*
  • Lung Neoplasms / blood supply*
  • Lung Neoplasms / drug therapy
  • Middle Aged
  • Neovascularization, Pathologic / drug therapy*
  • Vascular Endothelial Growth Factor A / physiology
  • Wound Healing

Substances

  • Angiogenesis Inhibitors
  • Heparin, Low-Molecular-Weight
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • bemiparin